OTCPicks.com: OTCPicks.com Stocks to Watch for Tuesday, June 9th SYNJ, MBRX, ANPI

Tue. June 09, 2009; Posted: 06:49 AM

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

SYNDICATION INCORPORATED (OTC: SYNJ | Quote | Chart | News | PowerRating) "Up 206.25% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/SYNJ.php

Syndication, Inc., a development stage company, operates as a consulting company in the United States. It acquires controlling interests in or to participate in the creation of, and to provide financial, management, and technical support to development stage businesses, e-commerce businesses, and traditional brick-and-mortar businesses. The company assists target companies in various areas, including the development and implementation of business models to provide solutions to traditional companies; building corporate infrastructure, such as a management team, a qualified sales and marketing department, information technology, and finance and business development; and managing rapid growth and flexibility to adopt to the changing Internet marketplace and technology. It also assists target companies in evaluating, structuring, and negotiating joint ventures, strategic alliances, joint marketing agreements and other corporate transactions; and by providing advice relating to corporate finance, financial reporting, and accounting operations. Syndication, through its subsidiary, Sy-Med Decompression, Inc., provides non-surgical treatment option for patients with back pain due to lumbar disc herniation, degenerative disc disease, sciatica, facet syndrome, and spinal stenosis. The company, formerly known as Syndication Net.com, Inc., was founded in 1999 and is headquartered in Washington, D.C.

SYNJ News:

June 5 - Syndication Inc. Announces McCutcheon Marshall Jr. as President and Chairman of the Board for Pinnacle Energy

Syndication Inc. (OTC: SYNJ | Quote | Chart | News | PowerRating) reports that, 17 days ago, on May 19th, 2009, the President and CEO of Sentinel Renewable Energies Inc., McCutcheon Marshall Jr., accepted the post of President and Chairman of the Board for Pinnacle Energy Inc., the wholly owned energy subsidiary of Syndication Inc.

Mr. Marshall's vision is to become a worldwide icon and leader in the alternative energy production industry. "He is equipped with the knowledge of the industry and controls the political cache to achieve that status," said Sorrentino, the CEO of Syndication Inc.

When asked to comment on his new appointment as President of Pinnacle Energy, Marshall stated, "My job is to direct the Federal and State financing in both the grant and loan activities for the Company as well as overseeing the general implementation of its business plan. Because of my relationship with Pinnacle, we have been able to move forward at an accelerated pace and achieve goals that I have been advised not to speak of at this time. I would yield to the advice of Mr. Sorrentino, the CEO of Syndication Inc.: 'It's best to hold our cards close to the chest for the time being,'" said McCutcheon Marshall Jr., the President of Pinnacle Energy Inc.

When the CEO of Syndication Inc., Mr. Sorrentino, was asked to comment on the appointment of the new President, he stated, "In my opinion, Mac is the best in the country and soon to be an icon in the alternative energy production industry, but, at this time, I don't like talking about it. Our competition reads like this: Saudi Arabia Oil; Qatar Petroleum; Abu Dhabi National Oil; Chevron Corporation, USA; Exxon Mobil, USA; and the list goes on and on. In fact, in the world of energy production, 'alternative energy' is the greatest threat to the existing industries profit margin. In my opinion, it's also a fact that in an effort to subsidize the ultimate shift in market profitability, they have launched attack teams to seek out 'upstart' companies and steal their potential markets in both financing and production capabilities. The thing that worries me most is that they have literally billions of dollars in assets to do it with. It is for these reasons that Mac and I have chosen not to release news on our many accomplishments already achieved. In the interest of my shareholders and the Company, it's best to be quiet for just a while," said Sorrentino, the CEO of Syndication Inc.

METABASIS THERAPEUTICS INCORPORATED (NASDAQ: MBRX | Quote | Chart | News | PowerRating) "Up 119.44% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/MBRX.php

Metabasis Therapeutics is a biopharmaceutical company committed to the discovery, development and commercialization of novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. The Company has established a broad pipeline of product candidates and advanced discovery programs targeting large markets with significant unmet needs. The Company's product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer. All of the Company's product candidates were developed internally using its proprietary technology and know-how.

MBRX News:

June 5 - Metabasis Therapeutics Receives a Development Event Payment from Roche and Notification That Roche Plans to Advance MB11362 into Development for the Treatment of Hepatitis C

Metabasis Therapeutics, Inc. (Nasdaq: MBRX | Quote | Chart | News | PowerRating) announced that it received a $2 million payment from Roche in recognition of advances made on their research collaboration, which is focused on applying Metabasis' HepDirect liver-targeting technology to Roche's proprietary lead nucleosides in order to develop new treatments for hepatitis C viral (HCV) infection. In addition, Metabasis announced that Roche has formally accepted MB11362 as a clinical candidate for development.

Metabasis and Roche entered into a collaboration and license agreement in August 2008 which included a $10 million upfront payment and provided for additional payments upon achievement of predetermined preclinical and clinical development events, as well as regulatory and commercialization events for each product, and royalties on net sales of products from the collaboration. As part of the collaboration, a HepDirect prodrug of a Roche proprietary nucleoside monophosphate was identified and evaluated in various pre-clinical studies conducted by scientists at Metabasis and Roche. The results of these studies led to a decision by Roche to advance MB11362 into pre-clinical development.

Metabasis reported last week that it had restructured the Company due to difficulties in raising capital from a financing or other sources. Metabasis continues to seek additional capital in the near-term, and if it is unsuccessful in raising additional capital, the Company may be forced to cease its operations entirely.

ANGIOTECH PHARMACEUTICALS INCORPORATED (NASDAQ: ANPI | Quote | Chart | News | PowerRating) "Up 39.41% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/ANPI.php

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.

ANPI News:

June 8 - Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option Inferior Vena Cava Filter

Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI | Quote | Chart | News | PowerRating) (TSX: ANP) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as previously announced in March 2008.

The Option IVC Filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted, typically by interventional radiologists in a minimally invasive procedure, into the body's inferior vena cava to prevent PE. Option is specifically designed for use as both a permanent or temporary implant (in temporary, or retrievable, indications, a physician may later perform a second surgical procedure to remove the Option IVC Filter if necessary or where mandated clinically).

"This important FDA clearance of the Option IVC Filter continues Angiotech's mission of offering the most highly innovative technology solutions to our physician customers and their patients," said Dr. William Hunter, President and CEO of Angiotech. "We are excited to commence commercial sales of Option through our dedicated Interventional Sales Team in the very near future. We believe the flexibility to use the Option IVC Filter in both permanent and retrievable indications, with clinical study data indicating 92% retrieval success, and a retrieval at up to 175 days post-implantation, provides Option the opportunity to be the market leading product in PE prevention."

According to market analysis conducted by Millennium Research Group, the U.S. market for IVC filters was approximately $200 million in 2007 (with approximately 160,000 IVC filters implanted). This market is predicted to grow to $300 million by 2012. IVC filters can be permanent or retrievable (where a physician can remove them when the patients no longer require them). Retrievable filters accounted for approximately two-thirds of the market in 2007. The Option IVC Filter is designed to be used in both permanent and retrievable indications and has been successfully retrieved at long intervals - up to 175 days post-implantation in the U.S. clinical trial.

The results of a recently concluded clinical trial for the Option IVC Filter were presented by the study's Principle Investigator, Dr. Matthew Johnson, at the 34th Annual Scientific Meeting of the Society of Interventional Radiology in March of 2009. The single-arm, multicenter clinical trial, which enrolled 100 patients with a mean age of 59 years, was designed to evaluate the safety and efficacy of the Option IVC filter when used both as a permanent and temporary filter in patients at increased risk for pulmonary embolism. In the trial, clinical success, defined as placement technical success without subsequent PE, significant filter migration or embolization, symptomatic thrombosis or other complications requiring filter removal or intervention, was achieved in 88% of subjects. Retrieval success was achieved in 92% (36/39) of cases where retrieval was attempted, with a mean implantation time in those cases of 67 days. The safety profile of the Option IVC Filter was consistent with other currently marketed IVC filters.

ABOUT THE OPTION INFERIOR VENA CAVA FILTER

The Option IVC filter, developed by Rex Medical, is specifically designed to facilitate long-term retrieval post device implantation if desired or deemed necessary by the treating physician, and can be used in the following conditions: pulmonary thromboembolism when anticoagulant therapy is contraindicated, failure of anticoagulant therapy in thromboembolic diseases, emergency treatment following massive PE, and chronic recurrent PE when anticoagulant therapy has failed or is contraindicated. The nitinol, Option(TM) IVC Filter, with a low profile delivery system, is designed with struts which direct clot volume into the center of the vessel for maximum dissolution and preservation of blood flow, allowing for capture of clinically significant clot and protection against PE. The self-centering filter facilitates optimal positioning and stability within the inferior vena cava.

ABOUT PULMONARY EMBOLISM (PE)

PE is an extremely common and highly lethal condition. PE is the sudden blocking of an artery of the lung (pulmonary artery) by a collection of solid material brought through the bloodstream (embolus) - usually a blood clot (thrombus) or other foreign material. PE occurs when these clots break loose and "embolize" to block pulmonary blood vessels in the lungs. According to clinical research, if left untreated, PE has a mortality rate of 30%. Emboli dislodgement can be caused by peripheral vascular disease (PVD), severe deep vein thrombosis (DVT), trauma and, prolonged immobilization often following a major surgical procedure.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Angiotech Pharmaceutical (ANPI) click here. Angiotech Pharmaceutical (ANPI) has Short Term PowerRatings of 4. Details on Angiotech Pharmaceutical (ANPI) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index